Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Prostatic Neoplasms 1Peritoneal Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × phenoxodiol × Clear all
NCT02941523 2021-06-02

Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours

Noxopharm Limited

Phase 1/2 Completed
19 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT00382811 2016-07-18

OVATURE

MEI Pharma, Inc.

Phase 3 Completed
142 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00091377 2016-07-14

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

MEI Pharma, Inc.

Phase 1/2 Completed
65 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00557037 2010-04-08

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

MEI Pharma, Inc.

Phase 2 Completed
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡